Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 2/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NMT2 | O60551 | 1/20 | 0.30 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494838 | 1.00 | GSR (0.38) | GSRCTSCRNPEPFOLH1SLC15A2 | |
| SCHEMBL2182070 | 0.87 | SLC6A5 (0.40) | GSRRNPEPFOLH1CPB2SLC6A5 | |
| SCHEMBL27898255 | 0.87 | F2 (0.38) | GSRCTSCRNPEPFOLH1SLC6A5 | |
| SCHEMBL10422593 | 0.86 | NMT2 (0.33) | GSRRNPEPFOLH1SLC15A2DPP8 | |
| SCHEMBL29198588 | 0.86 | FOLH1 (0.41) | GSRRNPEPFOLH1CPB2DPP8 | |
| SCHEMBL27535723 | 0.86 | SLC6A5 (0.45) | GSRFOLH1CPB2SLC6A5CYP2D6 | |
| SCHEMBL3717425 | 0.86 | SLC6A5 (0.45) | GSRFOLH1CPB2SLC6A5CYP2D6 | |
| SCHEMBL27849229 | 0.86 | DPP8 (0.37) | GSRRNPEPFOLH1CPB2DPP8 | |
| SCHEMBL10701105 | 0.84 | CTSC (0.36) | CTSC | |
| SCHEMBL28335157 | 0.83 | GSR (0.44) | GSRRNPEPFOLH1CPB2DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093425-A1 | Vitamin c derivatives with peptide, preparation method thereof and composition comprising the same | PEPTRON CO., LTD. (KR) | 2007-04-26 | — | — | US | claimed |
| US-20060160989-A1 | Polypeptide useful as antiallergic/antiasthmatic activity, methods for the preparation thereof, pharmaceutical compositions containing such polypeptide and use thereof | COUNCIL OF SCIENTIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-20 | — | — | US | claimed |
| EP-1348714-A1 | Polypeptide useful as anti-allergic/antiasthmatic, methods for the preparation thereof and pharmaceutical compositions containing such polypeptide and their use | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-10-01 | — | — | EP | claimed |
| US-4980343-A | Inhibit colon and rectal tumors | BAYER AKTIENGESELLSCHAFT (DE) | 1990-12-25 | — | — | US | claimed |
| EP-0365956-A2 | Carcinostatic agents | BAYER AG (DE) | 1990-05-02 | — | — | EP | claimed |
| US-20240060991-A1 | METHODS OF IDENTIFYING THE PRESENCE AND/OR CONCENTRATION AND/OR AMOUNT OF PROTEINS OR PROTEOMES | PROTEOTYPE DIAGNOSTICS LTD. (GB) | 2024-02-22 | — | — | US | disclosed |
| CN-117203527-A | Method for identifying the presence and/or concentration and/or amount of a protein or group of proteins | 蛋白类型诊断公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4196797-A1 | METHODS OF IDENTIFYING THE PRESENCE AND/OR CONCENTRATION AND/OR AMOUNT OF PROTEINS OR PROTEOMES | Proteotype Diagnostics Ltd (GB) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022034336-A1 | METHODS OF IDENTIFYING THE PRESENCE AND/OR CONCENTRATION AND/OR AMOUNT OF PROTEINS OR PROTEOMES | Proteotype Diagnostics Ltd (GB) | 2022-02-17 | — | — | WO | disclosed |
| US-20150111246-A1 | SITE-SPECIFIC ENZYMATIC MODIFICATION OF EXENDINS AND ANALOGS THEREOF | ASTRAZENECA PHARMACEUTICALS LP | 2015-04-23 | — | — | US | disclosed |
| EP-1348714-B1 | Polypeptide useful as anti-allergic/antiasthmatic, methods for the preparation thereof and pharmaceutical compositions containing such polypeptide and their use | COUNCIL SCIENT IND RES (IN) | 2007-01-03 | — | — | EP | disclosed |
| US-20060160989-A1 | Polypeptide useful as antiallergic/antiasthmatic activity, methods for the preparation thereof, pharmaceutical compositions containing such polypeptide and use thereof | COUNCIL OF SCIENTIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-20 | — | — | US | disclosed |
| EP-1348714-A1 | Polypeptide useful as anti-allergic/antiasthmatic, methods for the preparation thereof and pharmaceutical compositions containing such polypeptide and their use | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-10-01 | — | — | EP | disclosed |
| US-4980343-A | Inhibit colon and rectal tumors | BAYER AKTIENGESELLSCHAFT (DE) | 1990-12-25 | — | — | US | disclosed |
| EP-0365956-A2 | Carcinostatic agents | BAYER AG (DE) | 1990-05-02 | — | — | EP | disclosed |
| EP-0010297-B1 | DERIVATIVES OF POLYENE MACROLIDE ANTIBIOTICS CONTAINING AN AMINO SUGAR MOIETY, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1983-04-13 | — | — | EP | disclosed |
| US-4272525-A | FUNGICIDES | SCHERING CORPORATION (US) | 1981-06-09 | — | — | US | disclosed |
| EP-0010297-A1 | Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160989-A1 | Polypeptide useful as antiallergic/antiasthmatic activity, methods for the preparation thereof, pharmaceutical compositions containing such polypeptide and use thereof | NGLY1, ARGLU1, ARG1 | GSR 3918/4885CTSC 100/4885RNPEP 94/4885 |
| US-20070093425-A1 | Vitamin c derivatives with peptide, preparation method thereof and composition comprising the same | PROC, CTRC, GC | GSR 1879/4885CTSC 36/4885RNPEP 35/4885 |
| US-20150111246-A1 | SITE-SPECIFIC ENZYMATIC MODIFICATION OF EXENDINS AND ANALOGS THEREOF | ENPEP, PEPD, DNPEP | GSR 1460/4885CTSC 48/4885RNPEP 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.